Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2025Cancer

Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJiaying LianXZXianxu ZhuangYCYing Chen

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows Day 14 MRD predicts overall survival and event-free survival in AML patients, suggesting the importance of monitoring MRD.

Key Points

  • Patients with Day 14 MRD ≤1% had better overall survival and event-free survival rates, indicating improved prognostic outcomes.
  • Among 75 analyzed patients, 41.3% were classified as MRD 14-neg, and this group experienced significantly improved survival outcomes.
  • Retrospective analysis employed multiparametric flow cytometry to assess measurable residual disease in AML patients treated with VEN-AZA.
  • The findings underscore the potential benefits of monitoring MRD and the impact of factors like CSF3R status on AML prognosis.

Cite This Study

Lian et al. (2025) studied this question.

synapsesocial.com/papers/68af7e047567bf4f94ff5a1ahttps://doi.org/10.1002/cncr.70053
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis2025
  2. 2Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025
  3. 3Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax2025
  4. 4Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  5. 5Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.2025